Dr. Adhip Arora

Professional Journey

Achievements

• First Author and Lead Investigator of the landmark PLANeT Trial, published in Annals of Oncology (Impact Factor: 80.4).
• Internationally recognized for pioneering randomized clinical research in low-dose immunotherapy.
• Research presented at the ASCO Annual Meeting and the ESMO Congress.
• Recipient of the Outstanding Research Award (AIIMS Research Day).
• First Prize – Best of St. Gallen Breast Cancer Symposium.
• Author of multiple peer-reviewed publications and international conference presentations.
• Expertise in designing and conducting prospective investigator-initiated clinical trials.

Awards

• Outstanding Research Award, AIIMS Research Day
• First Prize, Best of St. Gallen Breast Cancer Symposium (SGBCS), Kolkata
• Research presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
• Research presented at the European Society for Medical Oncology (ESMO) Congress

Publication

ORIGINAL RESEARCH ARTICLES

• Arora A, Bhaskarane H, Tansir G, et al. A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (PLANeT trial—Pembrolizumab Low Dose in Addition to NACT in TNBC). Ann Oncol. 2025; 37:639-649.
• Arora A, Bhaskarane H, Tansir G, et al. Health-related quality of life with low-dose pembrolizumab plus chemotherapy in early triple-negative breast cancer: findings from the PLANeT trial. J Clin Oncol. 2026;44:607. doi: 10.1200/JCO.2026.44.16_suppl.607.
• Arora A, Seenu V, Parshad R, et al. A phase II, randomized, open-label study to evaluate low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC). Trials. 2025; 26:120. doi:10.1186/s13063-025-08726-9.
• Arora A, Seenu V, Parshad R, et al. 266TiP: A phase II, randomized, open-labelled study to evaluate low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC). ESMO Open. 2025;10(3):104820. doi: 10.1016/j.esmoop.2025.104820.
• Arora A, Chaudhary R, Arora S, Arora R. Correlation of carotid artery intima-media thickness with parameters of mineral bone disorder in patients with chronic kidney disease. Natl Med J India. 2026;39(1):13-18. doi:10.25259/NMJI_827_2022.
• Chaudhary R, Manocha R, Arora A. Correlation of fibroblast growth factor 23 and malnutrition in chronic kidney disease patients on maintenance hemodialysis. J Assoc Physicians India. 2022;70(4):11-12. PMID: 35443448.
• Arora A, Manocha R, Chaudhary R. Nephron index (urinary phosphate: serum fibroblast growth factor 23 ratio): a marker for atherosclerosis in diabetic predialysis chronic kidney disease patients. J Assoc Physicians India. 2022;70(4):11-12

CASE REPORTS

• Arora A. Isolated miliary tuberculosis of brain in an immuno-competent patient presenting as cerebellar ataxia. International Journal of Medical Science and Diagnosis Research. 2022.
• Arora A. Multiorgan failure due to paraquat poisoning: Case report and review of literature.
  Journal of Medical Science and Clinical Research. 2020.